Results 271 to 280 of about 76,021 (334)
Some of the next articles are maybe not open access.
Trends in Endocrinology and Metabolism, 2004
Mineralocorticoid resistance, also known as type I pseudohypoaldosteronism (PHA1), is a rare inherited disease characterized by salt wasting, dehydration and failure to thrive in the newborn. Two different forms of the disease, which present with either systemic or exclusively renal resistance to aldosterone, are associated with two different modes of ...
Maria-Christina, Zennaro, Marc, Lombès
openaire +2 more sources
Mineralocorticoid resistance, also known as type I pseudohypoaldosteronism (PHA1), is a rare inherited disease characterized by salt wasting, dehydration and failure to thrive in the newborn. Two different forms of the disease, which present with either systemic or exclusively renal resistance to aldosterone, are associated with two different modes of ...
Maria-Christina, Zennaro, Marc, Lombès
openaire +2 more sources
Steroids, 2000
The physiology of mineralocorticoid action, particularly with respect to epithelial sodium transport, is well defined. A full understanding of the molecular basis of mineralocorticoid action has however proven to be more elusive. In the last decade insights into structural and functional aspects of the mineralocorticoid receptor combined with emerging ...
F M, Rogerson, P J, Fuller
openaire +2 more sources
The physiology of mineralocorticoid action, particularly with respect to epithelial sodium transport, is well defined. A full understanding of the molecular basis of mineralocorticoid action has however proven to be more elusive. In the last decade insights into structural and functional aspects of the mineralocorticoid receptor combined with emerging ...
F M, Rogerson, P J, Fuller
openaire +2 more sources
Mineralocorticoid hypertension
The Lancet, 1999Hypertension with hypokalaemia and suppression of plasma renin activity is known as mineralocorticoid hypertension. Although mineralocorticoid hypertension accounts for a small number of patients labelled as having "essential" hypertension, it is a potentially reversible cause of high blood pressure.
openaire +2 more sources
Trends in Endocrinology & Metabolism, 1998
Adrenal Glands, Vascular System and Hypertension Edited by G.P. Vinson and D.C. Anderson. Bristol, UK, Society for Endocrinology, $95.00/ pound50.00 (312 pages), ISBN 1-898099-07-3.
openaire +2 more sources
Adrenal Glands, Vascular System and Hypertension Edited by G.P. Vinson and D.C. Anderson. Bristol, UK, Society for Endocrinology, $95.00/ pound50.00 (312 pages), ISBN 1-898099-07-3.
openaire +2 more sources
Steroids, 1996
Pseudohypoaldosteronism was first described in 1958 by Cheek and Perry, who reported an infant with severe salt wasting in the absence of any renal or adrenal defect. Since then several reports have described patients affected by symptoms consistent with resistance to mineralocorticoid action.
openaire +2 more sources
Pseudohypoaldosteronism was first described in 1958 by Cheek and Perry, who reported an infant with severe salt wasting in the absence of any renal or adrenal defect. Since then several reports have described patients affected by symptoms consistent with resistance to mineralocorticoid action.
openaire +2 more sources
Apparent mineralocorticoid excess
The Journal of Steroid Biochemistry and Molecular Biology, 1995Apparent mineralocorticoid excess is a syndrome reflecting the absent or impaired activity of the enzyme 11β-hydroxysteroid dehydrogenase Type 2. It may be mild when the mutant enzyme retains some activity, or severe when activity is absolutely or essentially absent.
openaire +3 more sources
Apparent mineralocorticoid excess
Trends in Endocrinology & Metabolism, 2001Apparent mineralocorticoid excess (AME) is a potentially fatal genetic disorder causing severe juvenile hypertension, pre- and postnatal growth failure, hypokalemia and low to undetectable levels of renin and aldosterone. It is caused by autosomal recessive mutations in the HSD11B2 gene, which result in a deficiency of 11 beta-hydroxysteroid ...
R C, Wilson, S, Nimkarn, M I, New
openaire +2 more sources
Mineralocorticoid receptor antagonists
Current Hypertension Reports, 2007With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan +1 more
openaire +3 more sources
Current Hypertension Reports, 2020
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta +2 more
openaire +2 more sources
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta +2 more
openaire +2 more sources